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Novel technologies are being developed to improve patient therapy through the identi-
fication of targets and surrogate molecular signatures that can help direct appropriate
treatment regimens for efficacy and drug safety. This is particularly the case in oncol-
ogy whereby patient tumor and biofluids are routinely isolated and analyzed for genetic,
immunohistochemical, and/or soluble markers to determine if a predictive biomarker sig-
nature (i.e., mutated gene product, differentially expressed protein, altered cell surface
antigen, etc.) exists as a means for selecting optimal treatment. These biomarkers may
be drug-specific targets and/or differentially expressed nucleic acids, proteins, or cell lin-
eage profiles that can directly affect the patient’s disease tissue or immune response to a
therapeutic regimen. Improvements in diagnostics that can prescreen predictive response
biomarker profiles will continue to optimize the ability to enhance patient therapy via molec-
ularly defined disease-specific treatment. Conversely, patients lacking predictive response
biomarkers will no longer needlessly be exposed to drugs that are unlikely to provide clinical
benefit, thereby enabling patients to pursue other therapeutic options and lowering over-
all healthcare costs by avoiding futile treatment. While patient molecular profiling offers a
powerful tool to direct treatment options, the difficulty in identifying disease-specific tar-
gets or predictive biomarker signatures that stratify a significant fraction within a disease
indication remains challenging. A goal for drug developers is to identify and implement new
strategies that can rapidly enable the development of beneficial disease-specific therapies
for broad patient-specific targeting without the need of tedious predictive biomarker dis-
covery and validation efforts, currently a bottleneck for development timelines. Successful
strategies may gain an advantage by employing repurposed, less-expensive existing agents
while potentially improving the therapeutic activity of novel, target-specific therapies that
may otherwise have off-target toxicities or less efficacy in cells exhibiting certain path-
ways. Here, we discuss the use of co-developing diagnostic-targeting vectors to identify
patients whose malignant tissue can specifically uptake a targeted anti-cancer drug vec-
tor prior to treatment. Using this system, a patient can be predetermined in real-time as
to whether or not their tumor(s) can specifically uptake a drug-linked diagnostic vector,
thus inferring the uptake of a similar vector linked to an anti-cancer agent. If tumor-specific
uptake is observed, then the patient may be suitable for drug-linked vector therapy and
have a higher likelihood of clinical benefit while patients with no tumor uptake should
consider other therapeutic options. This approach offers complementary opportunities to
rapidly develop broad tumor-specific agents for use in personalized medicine.
Keywords: companion diagnostics, CDx, co-development,TM601, theranostics, nanoparticles, naturally occurring
proteins, personalized medicine
PERSONALIZED MEDICINE IN THE ERA OF TARGETED
THERAPEUTIC STRATEGIES
Personalized medicine is generally considered as the precise use of
drug(s) that can specifically target a patient’s diseased tissue. This
is typically achieved by using a diagnostic biomarker or biomolec-
ular signature that can predict clinical response in patients before
they are treated (1). In the broadest sense, an example of person-
alized medicine can be found in the therapeutic management of
type 1 diabetes. Patients with this condition are identified initially
by abnormal blood glucose levels, whereby glucose serves as a bio-
marker. Once confirmed by follow-up testing, the disease can be
managed by drugs capable of modulating active insulin levels.
In more complex diseases such as cancer, an array of genetic
and altered gene product expression changes may be required to
determine or predict a patient’s specific response(s) to therapy.
Anti-cancer therapeutic strategies include: (i) binding to a specific
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molecular target of an altered pathway or a sequence-specific gene
product that in turn results in selective killing of malignant but
not normal cells; (ii) inducing a host immune response against
malignant cells; and (iii) enhancing specific uptake of an agent(s)
in target cells for disease suppression. Based on their chemical
or biochemical nature, targeted anti-cancer agents can be clas-
sified into small chemical entities (SCE) capable of disrupting
cellular processes such as enzymatic reactions, tubulin polymer-
ization and DNA replication; nucleic acids that can specifically
bind a gene product involved in tumor growth and metastasis;
and cellular- and protein-based therapies that can specifically tar-
get tumor-associated cell surface proteins or soluble ligands (2).
All these agents exert their pharmacologic activity by specifically
suppressing growth and survival in malignant vs. normal cells.
For targeted cancer therapies, it is important that the com-
pound can specifically bind to a gene product (e.g., lig-
ands/receptors, transcription factors, or enzymes) or a molec-
ular target within a pathway unique to a tumor cell or cells
located within the tumor microenvironment that support tumor
growth. These agents may include cell and protein-based vaccines,
peptides, recombinant proteins, antibodies, antibody fragments,
nucleic acid, and target-specific SCEs (2). The development of
novel SCEs targeting tumor-altered gene products involved in dri-
ving the underlying cause of transformation is expanding across
the industry as a result of recent approvals of compounds in this
class (3). These include the anti BCR–ABL fusion protein tyro-
sine kinase inhibitor imatinib (4) and the more recently approved
translocated ALK inhibitor, crizotinib (5), and mutant BRAF
inhibitor, vemurafenib (6). While this class has shown robust clin-
ical activity in patients containing the altered gene product, the
low target frequency of the latter two compounds has minimized
their utility in the greater patient population. Other classes of tar-
geted therapies include antibody and protein-based agents that can
specifically bind cell surface proteins on tumor cells and in turn
block or activate receptor signaling, induce programed cell death
and/or induce immune-mediated cytotoxicity. In all cases, patients
may be prescreened to determine if their tumor expresses an agent-
specific molecular target. These examples provide support for the
validity of discovering modified disease-specific gene products
that can serve as drug targets and be used to prescreen patients
via diagnostic platforms capable of identifying those eligible for
target-specific therapy.
Other personalized platforms include those that monitor gene
expression profiles or soluble markers contained within biofluids
(serum, plasma, urine, sputum, or whole cells) that may serve as
surrogates for predictive response to a therapeutic regimen. While
the example of type 1 diabetes fits into this category, broader dis-
covery approaches are being pursued in oncology. These include
biomarker signature profiles within disease tissue that may predict
response to certain chemotherapeutic regimens as well as modi-
fier genes that may predict response to a targeted therapy (7).
The use of tumor-specific biomarker signature profiles has been
widely pursued in breast cancer based on early successful prog-
nostic and therapeutic paradigms that relied on tumor stage and
grade, as well as HER2, estrogen (ER), and progesterone (PR)
receptor expression status. Subsequent efforts have further refined
breast cancer marker profiling to guide best course of therapy
(8). This was achieved by development of a molecular signature
panel comprising 21 genes, called Oncotype DX® (9), and sub-
sequently MammaPrint™ (10), which comprises a 70 gene set. In
both cases, surrogate gene expression profiles are measured to pre-
dict a patient’s prognosis and guidance for use of existing therapies.
More recently, a similar product for patient prognosis in colorectal
cancer (OncoDX) has been developed (11). While these molecular
signatures have value in predicting an individual’s prognosis, they
cannot predict potential clinical responses after specific targeted
therapy. Despite their success and widespread use in breast or col-
orectal cancer for clinical follow-up after initial diagnosis, the gen-
eration and validation of these gene product signatures has taken
a significant amount of time and effort before achieving clinical
utility in managing personalized treatment for cancer patients.
There are currently 19 FDA approved companion diagnostic
(CDx) assays, 18 of which are approved in oncology (Table 1). Ten
of the 18 CDx assays are various qualitative assays for detecting
HER2 expression or amplification in breast cancer; 2 are quali-
tative assays for BRAF V600E mutations; along with qualitative
assays for ALK translocations, KRAS mutations and c-KIT; and
3 qualitative assays for EGFR mutations. The relative paucity of
FDA approved CDx assays might reflect the difficulty and com-
plexity in requirements for approval of such assays but might also
be a reflection of a lack of in-depth knowledge of the underlying
biology of cancer and/or the drug target interaction. Further, it
is interesting to note that only 3 of the 18 (17%) oncology CDx
assays are quantitative in format. While quantitative assays are not
necessarily required, this undoubtedly speaks to the differences
in regulatory requirements for quantitative relative to qualitative
assays, at least with respect to CDx assays.
Interestingly, many more molecular diagnostic (Dx) assays are
in drug labels (Table 2) – not as companion diagnostics but rec-
ommended or even required prior to prescribing therapy or for
therapeutic monitoring – and some of these have been cleared by
the FDA through the 510(k) process (Table 3). Complex phar-
macogenomics signatures such as Oncotype DX® and even BRCA
mutation analyses (12) are routinely used in clinical oncology but
are performed under the CLIA regulation (Clinical Laboratory
Improvement Amendments of 1988) and are classified as Labora-
tory Developed Tests (LDTs). This class of Dx does not go through
the rigor of regulatory submissions such as 510(k) or PMA (Pre-
Market Approval; a CDx requires a PMA) nor the post-marketing
requirements of such assays. The FDA is currently reviewing and
is expected to make recommendations in the near future regard-
ing the oversight of LDTs, which may (significantly) change the
present landscape.
ANTIBODY-DRUG CONJUGATES AND
RADIOIMMUNOTHERAPIES
Recent clinical success of monoclonal antibody (mAb) drug con-
jugates (ADCs) has spurred the field of highly toxic chemother-
apeutic drugs for targeted therapy. The development of ADCs
offers dual benefits: the ability to preselect patients whose disease
expresses the target antigen for tumor-specific delivery and the
opportunity to deliver highly toxic (novel or repurposed) com-
pounds to antigen positive tumors while avoiding toxic off-target
effects commonly found with non-targeted SCEs or radionuclides
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Table 1 | FDA approved companion diagnostics (CDx).
Drug trade name
(generic name)
Device trade name Device manufacturer Approved Technology/indication
Erbitux (cetuximab) therascreen KRAS RGQ PCR Kit Qiagen 2012 Qualitative RT-PCR/CRC
Erbitux (cetuximab); Vectibix
(panitumumab)
DAKO EGFR PharmDx Kit Dako 2006 Qualitative IHC/CRC
Exjade (deferasirox) Ferriscan Resonance Health Analysis
Services
2013 FerriScan R2-MRI/thalassemia
Gilotrif (afatinib) Therascreen EGFR RGQ PCR Kit Qiagen 2013 Qualitative RT-PCR/NSCLC
Gleevec/glivec (imatinib
mesylate)
Dako C-KIT PharmDx Dako 2012 Qualitative IHC/GIST
INFORM HER2/neu Ventana Medical Systems 2000 Qualitative FISH/breast cancer
PathVysion HER2 DNA Probe Kit Abbott Molecular 2013 Qualitative FISH/breast cancer
PATHWAY anti-HER2/neu Ventana Medical Systems 2013 Semi-quantitative IHC/breast cancer
InSite HER2/neu Kit BioGenex Laboratories 2005 Semi-quantitative IHC/breast cancer
Herceptin (trastuzumab) SPOT-Light HER2 CISH Kit Life Technologies 2012 Quantitative CISH/breast cancer
Bond Oracle Her2 IHC System Leica Biosystems 2012 Semi-quantitative IHC/breast cancer
HER2 CISH PharmDx Kit Dako 2013 Quantitative ISH/breast cancer
INFORM HER2 Dual ISH DNA
Probe Cocktail
Ventana Medical Systems 2013 Two-color ISH/breast cancer
Herceptin (trastuzumab)
Perjeta (pertuzumab)
HercepTest Dako 2013 Semi-quantitative IHC/breast cancer,
metastatic gastric, or gastroesophageal
junction adenocarcinoma
KADCYLA (ado-trastuzumab
emtansine)
HER2 FISH PharmDx Kit Dako 2013 Quantitative FISH/breast cancer,
metastatic gastric, or gastroesophageal
junction adenocarcinoma
Mekinist (tramatenib); Tafinlar
(dabrafenib)
THxID™ BRAF Kit bioMérieux 2013 Qualitative RT-PCR/melanoma
Tarceva (erlotinib) Cobas EGFR Mutation Test Roche Molecular Systems 2013 Qualitative RT-PCR/NSCLC
Xalkori (crizotinib) Vysis ALK Break Apart FISH
Probe Kit
Abbott Molecular 2013 Qualitative FISH/NSCLC
Zelboraf (vemurafenib) Cobas 4800 BRAF V600
Mutation Test
Roche Molecular Systems 2013 Qualitative RT-PCR/melanoma
Source: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
(hereon referred to as cytotoxins) (13). Enhanced technologies
that enable robust linkage of a targeting agent to a cytotoxin
such as radionuclides, chemotherapeutic SCEs, and gene silenc-
ing nucleic acids has led to the establishment of a wide array of
next generation targeted therapies (14). The targeting moieties
themselves have varied from full-length antibodies to recombi-
nant proteins, small polypeptides, and nanoparticles (NPs). A
diversity of linkage chemistries that allow conjugation of a cyto-
toxin to the targeting agent have been implemented depending
upon where in the tissue it is most desirable to have the cyto-
toxin delivered and, if required, liberated from the targeting
agent. With the early success of antibody–cytotoxin conjugates
using radionuclides (referred to as radioimmunotherapy, RIT),
such as yttrium-90 (90Y)-labeled-ibritumomab tiuxetan (15) and
iodine-131 (131I)-labeled tositumomab (16) in treating refractory
lymphoma, as well as the recently approved ADC trastuzumab-
DM1 (T-DM1, Kadcyla®) (17), and brentuximab vedotin (SGN35,
Adcetris®) (18), significant progress in personalized medicine has
been attained (19). Part of this advancement is due to the improved
therapeutic activity over the parental agents (the cytotoxic or tar-
geting agent alone) resulting in a better clinical outcome while
minimizing toxicity. Rituximab is a chimeric mouse–human IgG1
mAb directed to the CD20 cell surface protein and approved
for treatment of B-cell lymphomas. 90Y-labeled-ibritumomab
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Table 2 | Molecular diagnostics (Dx) in US drug labels.
Drug HUGO symbol Referenced subgroup Labeling sections
Ado-trastuzumab
emtansine
ERBB2 HER2 protein overexpression or gene
amplification positive
Indications and usage, warnings and precautions, adverse
reactions, clinical pharmacology, clinical studies
Afatinib EGFR EGFR exon 19 deletion or exon 21
substitution (L858R) mutation positive
Indications and usage, dosage and administration, adverse
reactions, clinical pharmacology, clinical studies, patient
counseling information
Anastrozole ESR1, PGR Hormone receptor positive Indications and usage, clinical pharmacology, clinical studies
Arsenic trioxide PML/RARα PML/RARα [t(15;17)] gene expression
positive
Boxed warning, clinical pharmacology, indications and usage,
warnings
Bosutinib BCR/ABL1 Philadelphia chromosome [t(9;22)]
positive
Indications and usage, adverse reactions, clinical studies
Brentuximab vedotin TNFRSF8 CD30 positive Indications and usage, description, clinical pharmacology
Busulfan Philadelphia
chromosome
Ph chromosome negative Clinical studies
Capecitabine DPYD DPD deficient Contraindications, warnings and precautions, patient information
Cetuximab EGFR EGFR protein expression positive Indications and usage, warnings and precautions, description,
clinical pharmacology, clinical studies
KRAS KRAS codon 12 and 13 mutation
negative
Indications and usage, dosage and administration, warnings and
precautions, adverse reactions, clinical pharmacology, clinical
studies
Cisplatin TPMT TPMT intermediate or poor
metabolizers
Clinical pharmacology, warnings, precautions
Crizotinib ALK ALK gene rearrangement positive Indications and usage, dosage and administration, drug
interactions, warnings and precautions, adverse reactions, clinical
pharmacology, clinical studies
Dabrafenib BRAF BRAF V600E mutation positive Indications and usage, dosage and administration, warnings and
precautions, clinical pharmacology, clinical studies, patient
counseling information
G6PD G6PD deficient Warnings and precautions, adverse reactions, patient counseling
information
Dasatinib BCR/ABL1 Philadelphia chromosome [t(9;22)]
positive; T315I mutation posit
Indications and usage, clinical studies, patient counseling
information
Denileukin diftitox IL2RA CD25 antigen positive Indications and usage, warnings and precautions, clinical studies
Erlotinib EGFR EGFR protein expression positive
EGFR exon 19 deletion or exon 21
substitution (L858R) positive
Clinical pharmacology
Indications and usage, dosage and administration, clinical
pharmacology, clinical studies
Everolimus ERBB2 HER2 protein overexpression negative Indications and usage, boxed warning, adverse reactions, use in
specific populations, clinical pharmacology, clinical studies
Everolimus ESR1 Estrogen receptor positive Clinical pharmacology, clinical studies
Exemestane ESR1 Estrogen receptor positive Indications and usage, dosage and administration, clinical studies,
clinical pharmacology
(Continued)
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Table 2 | Continued
Drug HUGO symbol Referenced subgroup Labeling sections
Fluorouracil DPYD DPD deficient Warnings
Fulvestrant ESR1 Estrogen receptor positive Indications and usage, clinical pharmacology, clinical studies,
patient counseling information
Ibritumomab
tiuxetan
MS4A1 CD20 positive Indications and usage, clinical pharmacology, description
Imatinib KIT c-KIT D816V mutation negative Indications and usage, dosage and administration clinical
pharmacology, clinical studiesBCR/ABL1 Philadelphia chromosome [t(9;22)]
positive
PDGFRβ PDGFR gene rearrangement positive
FIP1L1/PDGFRα FIP1L1/PDGFRα fusion kinase (or
CHIC2 deletion) positive
Indications and usage, dosage and administration, clinical studies
Irinotecan UGT1A1 UGT1A1*28 allele carriers Dosage and administration, warnings, clinical pharmacology
Lapatinib ERBB2 HER2 protein overexpression positive Indications and usage, clinical pharmacology, patient counseling
information
Letrozole ESR1, PGR Hormone receptor positive Indications and usage, adverse reactions, clinical studies, clinical
pharmacology
Mercaptopurine TPMT TPMT intermediate or poor
metabolizers
Dosage and administration, contraindications, precautions,
adverse reactions, clinical pharmacology
Nilotinib BCR/ABL1 Philadelphia chromosome [t(9;22)]
positive
Indications and usage, patient counseling information
Nilotinib UGT1A1 UGT1A1*28 allele homozygotes Warnings and precautions, clinical pharmacology
Ofatumumab MS4A1 CD20 positive Indications and usage, clinical pharmacology
Omacetaxine BCR/ABL1 BCR-ABL T315I Clinical pharmacology
Panitumumab EGFR EGFR protein expression positive Indications and usage, warnings and precautions, clinical
pharmacology, clinical studies
KRAS KRAS codon 12 and 13 mutation
negative
Indications and usage, clinical pharmacology, clinical studies
Pazopanib UGT1A1 (TA)7/(TA)7 genotype
(UGT1A1*28/*28)
Clinical pharmacology, warnings and precautions
Pertuzumab ERBB2 HER2 protein overexpression positive Indications and usage, warnings and precautions, adverse
reactions, clinical studies, clinical pharmacology
Ponatinib BCR/ABL1 Philadelphia chromosome [t(9;22)]
positive, BCR–ABL T315I mutation
Indications and usage, warnings and precautions, adverse
reactions, use in specific populations, clinical pharmacology,
clinical studies
Rasburicase G6PD G6PD deficient Boxed warning, contraindications
Rituximab MS4A1 CD20 positive Indication and usage, clinical pharmacology, description,
precautions
(Continued)
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Table 2 | Continued
Drug HUGO symbol Referenced subgroup Labeling sections
Tamoxifen ESR1, PGR Hormone receptor positive Indications and usage, precautions, medication guide
F5 Factor V Leiden carriers Warnings
F2 Prothrombin mutation G20210A
Thioguanine TPMT TPMT poor metabolizer Dosage and administration, precautions, warnings
Tositumomab MS4A1 CD20 antigen positive Indications and usage, clinical pharmacology
Trametinib BRAF BRAF V600E/K mutation positive Indications and usage, dosage and administration, adverse
reactions, clinical pharmacology, clinical studies, patient
counseling information
Trastuzumab ERBB2 HER2 protein overexpression
positive
Indications and usage, warnings and precautions, clinical
pharmacology, clinical studies
Tretinoin PML/RARA PML/RARα [t(15;17)] gene
expression positive
Clinical studies, indications and usage, warnings
Vemurafenib BRAF BRAF V600E mutation positive Indications and usage, warning and precautions, clinical
pharmacology, clinical studies, patient counseling
information
Source: http:// www.fda.gov/ Drugs/ ScienceResearch/ ResearchAreas/ Pharmacogenetics/ ucm083378.htm
tiuxetan and I131-labeled tositumomab, both of which also tar-
get CD20, showed statistically significant clinical responses in
patients as compared to rituximab or chemotherapy alone and
were approved for use in rituximab-refractory patients. Unfortu-
nately, the application of these RITs in clinical practice has been
limited by the complexity of handling β-emitting radionuclide-
labeled mAbs before and after patient treatment. These limitations
have fostered the generation of alternate molecules, including
alpha emitting RITs (20) as well as non-radioactive cytotoxins that
can be more practically conjugated to mAb, protein, or peptide-
based targeting agents, without affecting their pharmacokinetic
or pharmacodynamic properties (i.e., diminished ability to max-
imally and specifically access its target expressed by the diseased
tissue). While therapeutic improvements have been reported in
cancers using RITs and ADCs vs. non-conjugated agents, not all
patients treated with RIT or ADC agents have shown enhanced
benefit, suggesting diagnostic opportunities for improving the
therapeutic use of conjugates (21). Table 4 provides an overview
of approved ADCs and RITs.
As indicated above, continued improvement and development
of targeted therapies, using ADCs, RITs, or other technologies,
is required but not sufficient to realize the maximal therapeu-
tic potential of personalized medicine. Tailoring of a therapy
to an individual’s cancer requires knowledge of the underlying
biology of that cancer and may involve utilizing surrogate mol-
ecular signatures, drug target expression profiles, and/or degree
of targeted conjugate uptake for predicting patient response. The
heterogeneity described for individual tumors (22) only adds to
the complexity of defining the biomolecular characteristics of a
patient’s malignant tissue and selecting a therapy, or combination
of therapies, most likely to be effective for the individual patient.
In turn, such tumor heterogeneity adds to the complexity of devel-
opment of the requisite surrogate Dx or CDx that is required to
maximize the benefit of targeted therapies. It is generally accepted
that the more complex the diagnostic platform, the more intricate
is the regulatory path for approval, especially if the diagnostic is a
CDx. A CDx is considered high risk by most regulatory authori-
ties as it specifically dictates therapeutic intervention, in contrast
to Oncotype Dx, MammaPrint, or OncoDX type diagnostic tools
that merely supply information relative to prognosis and guide
the therapeutic intervention. The development, analytical, and
clinical validation of complex multi-marker diagnostic biomarker
signatures is both time consuming and expensive. In addition,
the alignment of therapeutic-diagnostic development timelines is
challenging at best, especially if such signatures are not discov-
ered until post hoc analysis of Phase 2 clinical trials. The recent
clearance by the US FDA of next generation sequencing (NGS)
instrumentation for cystic fibrosis is an important step for the use
of new technologies to support complex assay developments, par-
ticularly as they relate to oncology where such complex signatures
are likely required (23). However, as noted, biomarker signatures
for predicting response to a given therapy may not simply involve
gene expression or mutation profiles but, rather, complex gene
product expression profiles.
TARGETED CYTOTOXIC AGENTS – TCAs
Despite the successful demonstration that targeted cytotoxic
agents (TCAs), such as ADCs and RITs, can provide added clinical
benefit for certain cancers, a number of challenges still remain for
their clinical success across a broad spectrum of cancer indica-
tions. The effectiveness of targeted cytotoxin conjugates depends
in part on the inherent features of the conjugate used. Some of the
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Table 3 | FDA 510(k) cleared molecular diagnostics (Dx).
Disease state Device Year Device manufacturer Comments
AML Vysis EGR1 FISH
Probe Kit
2011 Abbott Molecular Deletions in EGR1; bone marrow specimens; aid in prognosis
B-cell CLL Vysis CLL FISH
Probe Kit
2011 Vysis Deletions in TP53, ATM, and D1I3S319 and gain in D1I2Z3; peripheral
blood; aid in prognosis
CEP 12 DNA Probe 1997 Vysis FISH; specific for centromere 12; peripheral blood; prognosis
Bladder cancer Vysis UroVysion
Bladder Cancer
Recurrence Kit
2004 Vysis Aneuploidy of chromosomes 3, 7, 17 and loss of 9p21 locus; urine
specimens; TCC; monitor recurrence
Breast cancer MammaPrint 2011 Agendia Gene expression profile; fresh frozen tissue; assess risk for distant
metastasis and prognosis
GeneSearch Breast
Lymph Node (BLN)
Test Kit
2009 Veridex Gene expression panel; metastasis in lymph nodes; aids in the
decision to excise additional lymph nodes and staging
Dako TOP2A FISH
PharmDx Kit
2012 Dako FISH to detect copy number changes of TOP2A; FFPE; prognosis in
high risk breast cancer patients
Cystic fibrosis eSensor CF
Genotyping Test
2009 Osmetech Molecular
Diagnostics
Detects a panel of mutations and variants in CFTR; genomic DNA;
genetic carrier screening
xTAG Cystic Fibrosis
60 Kit v2
2009 Luminex Molecular
Diagnostics
Detects and identifies a panel of mutations and variants the CFTR;
genetic carrier and newborn screening
Prostate cancer NADiA ProsVue 2011 Iris Molecular
Diagnostics
Determines rate of change of total PSA; serum; an aid in identifying
those patients at reduced risk for recurrence of prostate cancer
PROGENSA PCA3
Assay
2012 Gen-Probe PCA3 and PSA RNA ratio; urine; aids physicians in determining the
need for repeat prostate biopsies in men who have had a previous
negative biopsy
Tissue of origin Pathwork Tissue of
OriginTest Kit – FFPE
2012 Pathwork
Diagnostics
Compares RNA expression patterns in a patient’s FFPE tumor with
those in a database; tissue; aid in determining origin of cancer
Pathwork Tissue of
Origin Test
2008 Pathwork
Diagnostics
Compares RNA expression patterns in a patient’s fresh/frozen tumor
with those in a database; tissue; aid in determining origin of cancer
Source: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm
TCA properties that can be optimized include: (1) tumor recog-
nition and penetration; (2) serum half-life to minimize liberation
of the cytotoxin in serum that may result in off-target effects;
(3) targeting epitopes on a cell surface antigen that can support
maximal conjugate internalization; (4) ability of the targeting
agent to retain its target specificity in the conjugated form; and
(5) large-scale conjugation of the cytotoxin to the targeting moi-
ety for GMP manufacturing at a reasonable cost-of-goods. Smaller
molecular weight targeting conjugates that employ antibody frag-
ment or peptide platforms offer the opportunity to improve TCA
tumor penetration (21), enhance binding specificities (24) and
internalization (25), as well as lower serum half-lives to avoid pro-
longed circulation (26). Furthermore, smaller sized TCAs offer
the ability to employ alternative manufacturing approaches to
minimize cost-of-goods in contrast to mammalian cell fermenta-
tion that is required for manufacturing of full-length monoclonal
antibodies. While antibody and antibody fragment conjugates
appear to offer additional benefits for developing disease-specific
therapies, the limited frequency in which a cell surface target is
strictly expressed across heterogeneous disease vs. normal tissue
remains a major drawback. In cancer, several cell surface targets
have been identified that appear to be tumor-specific but the
frequency of expression is quite variable from one tumor type
to another thereby limiting the breadth by which an approved
TCA can be used across different cancer indications (27). Fur-
thermore, recent studies have demonstrated that the expression
levels and/or distribution of cell surface targets on tumor cells or
tumor-associated stromal cells can vary within the same specimen
(28). Hence, the development of high affinity and high speci-
ficity targeting agents to maximize tumor recognition in cases
of low and heterogeneous target expression is needed. The num-
ber of broadly expressed molecular targets that are present on
a diseased cell and not on normal tissues that can be selectively
targeted by a TCA is low. Nevertheless, several disease-specific
antigens have been identified as a result of epigenetic mechanisms,
alternative splicing, gene rearrangement, and overexpression that
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Table 4 | Examples of approved antibody-drug conjugates (ADCs) and radioimmunotherapeutics (RIT’s) in oncology.
Trade name
(generic)
Manufacturer Target Conjugate Approved Indication Comments
ANTIBODY-DRUG CONJUGATES (ADCs)
Mylotarg
Gemtuzumab
ozogamicin
Pfizer/Wyeth CD33 Calecheamicin 2001 Recurrent AML (age 60+) Voluntarily withdrawn in 2010, due to
product safety issues and lack of clinical
benefit
Adcetris
Brentuximab
vedotin
Seattle Genetics CD30 Mono-methyl
auristatin E
(MMAE)
2011 Refractory Hodgkin’s lymphoma
Refractory systemic anaplastic
large cell lymphoma
Kadcyla
Trastuzumab
emtansine
Genentech/
Roche
Her2/
neu
Maytansinoid
DM1
2013 HER2-positive metastatic breast
cancer
Approved for patients who have received
prior treatment with Herceptin®
(trastuzumab) and a taxane chemotherapy
Trade name
(generic)
Manufacturer Target Isotope Approved Indication Comments
RADIOIMMUNOTHERAPEUTICS (RITs)
Zevalin
Ibritumomab
tiuxetan
Biogen-Idec/
Spectrum
pharmaceuticals
CD20 90Y 2002 Recurrent, low-grade or follicular
B-cell non-Hodgkin’s lymphoma
Bexxar
Iodine (131I)
tositumomab
Corixa/GSK CD20 131I 2003 CD20 positive, follicular NHL,
refractory to rituximab and
relapsed following chemotherapy
Manufacture discontinued in 2014 due to
poor sales
support the potential use of this class for maximizing the thera-
peutic potential of targeted agents (27). As efforts continue across
the industry to identify more disease-specific targets via a vari-
ety of genomic and proteomic discovery approaches (discussed
below), more broadly expressed disease-associated targets and dis-
ease targeting agents have been identified from the screening of
naturally occurring pathogenic proteins, intra-protein domains,
and NPs scaffolds (29–31). These platforms offer the potential to
employ theranostics: the co-development of a TCA along with
the same targeting vector linked to a diagnostic agent to deter-
mine effective targeting and patient selection (32). Moreover,
the use of TCA formats enables the potential repurposing of
pharmacologically defined cytotoxic agents on the market, which
may lead to faster development timelines of TCA by leveraging
prior clinical experience, or the salvaging of compounds that
showed anti-tumor activity in clinical trials but failed due to
off-target toxicities. One should also bear in mind that, while
the expression of the target is required, it may not be sufficient
for long-lasting responses. In fact, due to the inherent hetero-
geneity of tumors and potential escape mechanisms [as seen
for example with BRAF inhibitors (33)], theranostics and the
TCA strategy in general would likely benefit from being com-
bined with other drugs that have different mode of action and/or
target.
NANOPARTICLES AND APTAMERS
Over the past two decades, the use of NPs has shown promise in
delivering therapeutic drugs to malignant cells. Early NP-derived
agents were primarily designed by optimizing particle size, chem-
ical composition (lipids, silica, nucleic acids), and charge in an
attempt to deliver tumor-specificity (34). Next generation NP
technologies incorporated the use of disease-specific ligands, such
as antibodies and aptamers, which could bind to disease-associated
cell surface receptors and deliver therapeutic SCEs. Unfortunately,
as mentioned above, the discovery of widely expressed disease-
specific receptors that can mediate robust internalization are infre-
quent. More recently, aptamer-bound NPs have been found to be
useful in delivering cytotoxic agents to cancers by targeting disease-
specific epitopes on cell surface tumor antigens (35). Peptide
aptamers are combinatorial protein molecules usually consisting
of short peptides inserted within a scaffold protein resulting in
conformational assortment that creates a target-binding diver-
sity. Nucleic acid-based aptamers can achieve similar levels of
conformational diversity and target specificity as peptide-based
aptamers. Since nucleic acids are also being explored as NP to carry,
deliver, and release chemotherapeutic agents, they may represent
unique building blocks for both aptamers and NPs manufactur-
ing. The use of aptamers expands the ability to identify subtle
differences in the topographical structure of cell surface tumor
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antigen motifs that are not as easily recognized by traditional
proteomic platforms. In light of their size, aptamer-guided NPs
have been further engineered as theranostics, whereby the NP
contains the targeting aptamer, a cytotoxic agent and an imaging
agent that can monitor tumor uptake directly in the patient (36).
Patients showing tumor-specific uptake are then deemed suitable
for NP-cytotoxic therapy while those that do not can pursue other
therapeutic options. Again, despite these promising results, chal-
lenges still remain in aptamer-guided NP theranostics including
non-specific NP tissue binding, systemic stability, GMP manufac-
turing, and broad-based application to multiple cancer types. It
is worth noting that the successful development of targeted NPs
will be demonstrated through a combination of target specificity,
a high tumor-to-normal tissue ratio and affinity that will enable
the agent to “find and bind” low target expression to deliver their
cytotoxic payload. Similarly, these properties are required for their
use in diagnostic modalities including patient selection and mon-
itoring of therapeutic efficacy. Table 5 contains a list of marketed
and clinical stage NPs being developed for oncology.
NATURAL AGENTS TARGETING TUMORS
Several natural agents are able to target differentially expressed
or conformation-specific cell surface antigens that are not eas-
ily identified by nucleic acid or proteomic analyses nor are easily
targeted using traditional protein/antibody approaches. In par-
ticular, proteins, toxins or metabolites contained within plants,
insects, arthropods, reptiles, viruses, and bacteria have yielded a
number of agents capable of binding to specific host cell surface
and intracellular proteins as a means to defend against predators
and/or suppress their immune system as well as paralyze or even
kill their prey (37, 38). Biochemical studies using natural agents
from these sources have found them to have disparate activities.
These include those that bind and are retained on the cell surface
to suppress the activity of enzymes and channels while others
have been shown to internalize upon binding to cell type-specific
cell surface proteins to suppress intracellular functions. Naturally
occurring polypeptides (NOP) from these sources include the fol-
lowing agents: vacuolating toxin A (VacA), which enters human
cells via sphingomyelin (39); hepatitis C viral coat protein, which
enters cells via claudin-1 (40);Clostridiumperfringens enterotoxin,
which binds to claudin-4 and causes cytotoxicity in cancer cells
(41); crotamine, a toxin from rattlesnake venom that enters cells
via heparin sulfate proteoglycans (42); and cholorotoxin, which
binds to activated epithelial cells and internalizes via the annexin
A2 complex (43, 44). Upon further experimental validation of
tumor selectivity, any of these agents may serve as potential target-
ing moieties in the context of a TCA and could also be incorporated
into theranostics platforms.
A critical factor for a therapeutic conjugate to provide clini-
cal benefit is the ability to be systemically maintained at a certain
molar level in order for the drug to effectively reach the target cells
and accumulate at a concentration sufficient for the cytotoxin to
exert its pharmacologic effect. Potential drawbacks of using NPs
are their relative short serum and intracellular half-lives making
extensive dosing and formulation studies critical for their success
(45). Alternatively, NOPs have been selected by nature for their
ability to impact cellular targets and maintain their function upon
exposure. Moreover, their structures have evolved to withstand
systemic degradation and immune responses by the host’s serum
proteolytic and host defense systems. These features along with
Table 5 | Examples of clinical stage nanoparticles and naturally occurring proteins in development for oncology.
Organization Compound name Compound description Target/active agent Development stage
Alnylam
Pharmaceuticals
ALN-VSP Liposomal based nanoparticle containing siRNA KSD and VEGF/siRNA Phase 1
BIND Biosciences Bind-014 Polylactide–polyethylene glycol biopolymer nanoparticle
containing a chemotoxin and targeting ligand
PSMA/docetaxel Phase 2
Celgene Nab-paclitaxel Albumin based nanoparticle Paclitaxel Approved
(Abraxane®)
Cerulean Pharma CRLX-101 Cyclodextrin-based nanoparticle encapsulating a
chemotoxin
Camptothecin Phase 1/2
Janssen
Pharmaceuticals
Pegylated liposomal
doxorubicin
Pegylated liposomal nanoparticle containing a
chemotoxin
Doxorubicin Approved (Doxil®)
Morphotek TM601 36 Amino acid peptide from scorpion venom that binds
transformed cells and tumor endothelial cells via
annexin A2 complex
Annexin A2 complex Phase 1 (naked
peptide format)
University of
Illinois at Chicago
NSC745104 28 Amino acid fragment of the protein cupredoxin
azurin from pseudomonas aeruginosa that increases
intracellular p53 concentrations
p53 Phase 1
KSD, kinesin spindle protein; PSMA, prostate-specific membrane antigen; VEGF, vascular endothelial growth factor.
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their small molecular size warrant exploring NOP potential appli-
cations in theranostics platforms and large-scale manufacturing
for development. Furthermore, NOPs could find applications in
immunohistochemistry and potentially in biofluid-based assays
for soluble ligands or in the detection of specific circulating tumor
cells (CTCs).
Screening of natural peptides and cell penetrating peptides may
offer an advantage for rapid development of targeted therapy
by using cell-specific uptake as a predictive marker for thera-
peutic benefit. This approach may offer a more rapid approach
for developing personalized medicines over traditional molecular
association, pharmacogenomic, and/or gene signature platforms
that may require longer timelines for discovery and validation.
However, the use of the latter can be combined during develop-
ment once biomarker signature profiles have been reproducibly
validated for predictive responses to treatment for a disease or
disease-specific targeting agent. Table 5 contains a list of some
NOPs being developed for oncology.
EXAMPLE OF NATURALLY OCCURRING POLYPEPTIDE:
CHLOROTOXIN
Chlorotoxin (CTX) is one of several NOPs that may be utilized
for development of theranostics. Protein fractions of the venom
from the Israeli scorpion, Leirius quinquestriatus were screened
for the ability to selectively suppress tumor cell growth while leav-
ing normal epithelial cells unaffected (46). This effort identified
a 36 amino acid peptide (CTX) that is able to preferentially bind
tumor vs. normal epithelial cells and perturb cell growth. Mol-
ecular studies have suggested that CTX binds and internalizes
into a wide range of tumor types via the annexin A2 complex,
a ubiquitously expressed intracellular protein in normal cells that
is found expressed in complexes on the exterior surface of extra-
cellular membranes of transformed cells (44). Preclinical studies
have shown the ability of CTX to deliver radionuclides, complex
dyes, as well as NPs preferentially to tumor cells in vitro and in vivo
(47). In addition, preclinical studies have also shown CTX to have
antiangiogenic activity as a naked peptide (48). Synthetic CTX has
been tested in clinical trials and has shown the ability to deliver
specifically conjugated 131I-radionuclide to tumors after local or
systemic delivery with no detectable uptake observed in normal
tissues (49) as well as affect angiogenesis as a naked peptide in a
Phase 1 trial. The platform is currently being expanded for diag-
nostic applications (49) and for delivery of cytotoxic compounds
including radionuclides to tumors (unpublished observations).
The preclinical and clinical studies reported to date suggest a nat-
ural compound like CTX could be formatted as a theranostic agent
to support personalized medicine. This would be beneficial in light
of the broad presence of cell surface annexin A2 complexes in
transformed vs. normal cells.
Several studies have provided examples of how CTX could
potentially be used as a theranostic agent for cancer. These include
imaging studies demonstrating CTX conjugate localization to
tumors vs. normal tissues. In one format, CTX has been devel-
oped as an imaging bioconjugate composed of CTX and Cy5.5,
a fluorescent agent that emits photons in the near-IR spectrum
(49). The bioconjugate has been shown to be useful in detecting
cancer foci and metastases non-invasively under surgical operating
conditions. Systemically, a CTX radionuclide conjugate has been
shown to detect metastatic lesions in cancer patients with periph-
eral and CNS disease (50). Ongoing efforts are aimed at selecting
the payload(s) with theranostic features as well as optimizing
conjugation chemistry for delivering both a cytotoxin and a tracer
to the tumor site.
THERANOSTICS CHALLENGES AND OPPORTUNITIES: USE OF
CO-DEVELOPING DIAGNOSTIC AND THERAPEUTIC
TARGETING VECTORS
The definition of theranostics (the merging of the words thera-
peutics with diagnostics) can be very broad. In its most traditional
sense of diagnostics-guided therapy, the concept of theranostics
can be identified in the previously cited example, whereby glucose
blood levels are measured to determine the timing of the treatment
as well as which patients will benefit the most from a hormone
(insulin)-based therapy. Nowadays, detecting BRAF mutation is
equivalent to measuring blood glucose in that it allows identi-
fying which cancer patients would benefit from an anti-cancer
agent targeting a specific kinase (e.g., targeted theranostics against
mutated BRAF). In both examples, the diagnostic tool and the
therapeutic agent are completely different because they share no
molecular components. On the other hand, these two examples
differ at least in one regard: while glucose levels represent a “non-
targeted”biomarker of the disease state (the true therapeutic target
being insulin receptor),detection of BRAF mutation underpins the
very presence of the target against which the targeted therapeu-
tic agent has an inhibitory effect. The mutated BRAF constitutes
both a therapeutic target as well as a disease biomarker. In another
incarnation of targeted theranostics, the targeting agent could be
employed in both the diagnostics and therapeutics strategy. In this
instance, the diagnostic and the therapeutic agents do share at least
one molecular component. Let us call it “leveraged theranostics.”
Hence, we can describe at least three different theranostics classes:
non-targeted, targeted, and leveraged (Figure 1).
FIGURE 1 |Types of theranostic agents. In non-targeted theranostics (left
panel), the biomarker (BM), the diagnostics (Dx) tool, the target, and the
therapeutic agent (Rx) are separate entities. In the targeted theranostics
(middle panel), the target and the biomarker are one and the same, but the
Dx tool and the Rx are separate entities. In the leveraged theranostics (right
panel), the diagnostic and the therapeutic agent share molecular
components.
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Monoclonal antibodies, antibody fragments, NPs, or NOPs may
be armed with payloads and deployed in a leveraged theranostic
strategy through the clever use of chemical linkers or couplers. One
can envision three basic configurations for a leveraged theranostic
compound: (1) one payload for therapy and one for diagnostics,
with these payloads conjugated on different batches of the same
targeting molecule; this configuration involves a single manufac-
turing process for the targeting moiety, and possibly one process
for the linker attachment, but two separate processes for the con-
jugation of the two payload types; (2) one payload for therapy and
one for diagnostics co-conjugated on the same targeting moiety;
this implies a single compound and manufacturing process and
represents a more ideal scenario; and finally (3) a single payload
that can be cytotoxic as well as used for tumor uptake monitoring;
this configuration allows for a single compound, manufacturing
and conjugation process represents the most ideal scenario. An
example of the first configuration (Figure 2A) is offered by the
use of specific radionuclides. A radionuclide could be optimal for
cytotoxicity but suboptimal for imaging, or vice versa. However,
even by using currently available radionuclides, a single target-
ing agent such as CTX could be “functionalized” using a single
chelator (hence a single manufacturing process for the targeting,
functionalized moiety), and conjugated to Indium-111 for patient
selection and Yttrium-90 for delivering cytotoxicity to the tumor
by using two separate conjugation processes. Indium-111, while
an excellent imaging agent, is not useful for therapy due to its
low tissue penetration characteristic. These properties are reversed
in Yttrium-90. Other radionucleotide pairs could be selected to
satisfy the desired pharmacological as well as pharmacodynamic
properties of the theranostic agent being pursued.
In the second configuration (Figure 2B), one where both pay-
loads are co-attached on the same targeting molecule, one needs to
be mindful of stereochemical interferences. For example, multiple
payloads can disrupt the tumor cell binding activity of small tar-
geting peptides such as CTX (36 amino acids). Structure–activity
relationship analysis would need to be conducted to identify the
best chemistry and attachment sites on both the targeting and
payload molecules. NPs inherently offer the opportunity to carry
multiple payloads to the tumor, including cytotoxins and diag-
nostic agents, but may not be sufficiently tumor-specific unless
coupled with a targeting moiety. Another challenge using multiple
payloads could be achieving a defined chemical homogeneity nec-
essary for regulatory approval using a cost-effective manufacturing
process.
The third configuration type (Figure 2C) has been achieved
over the past several years by employing iodine-131, which,
as noted above, suffers from the complexity of its handling.
Therefore, this configuration could be improved by the selec-
tion of optimized radionuclides, their improved manufacturing
processes, storage, and handling procedures, and by more sen-
sitive whole-body radio-imaging devices. A new candidate for
this mono-payload theranostic strategy is lutetium-177 (51). This
radionuclide is a medium-energy β-emitter with a maximal tis-
sue penetration of 2 mm, hence capable of delivering its cytotoxic
energy through several cell layers, while potentially having less
off-target toxicity than yttrium-90 (12 mm penetration range).
Lutetium-177 also emits low-energy γ-rays allowing both imaging
FIGURE 2 | Configurations of theranostic agents: (A) two separate
batches of the same targeting moiety (in this example a mAb) are
conjugated with either a therapeutic agent (Rx) such as a cytotoxin, or
a diagnostic agent (Dx) such as a radionuclide; (B) the same batch of a
mAb is conjugated with both Rx and Dx agents on the same targeting
molecule; and (C) the same batch of a mAb is conjugated with an
agent having both Rx and Dx properties (R/Dx), such as Lutetium-177,
on the same targeting molecule.
and dosimetry (quantitation of delivered or residual dose). Mono-
payload, radiolabeled compounds could be used theranostically,
whereby: (i) low, diagnostic (non-therapeutic) doses are used for
initial assessment of in vivo targeting; (ii) sub-therapeutic doses
are administered for dosimetry, allowing precise dose selection,
and for monitoring potential toxic effect; and (iii) higher, ther-
apeutic doses are administered to continue to monitor toxicity
in conjunction with tumor burden (efficacy, acquired resistance)
and tumor uptake (disease modifications, such as loss of tar-
get). This strategy is already being implemented when using
BEXXAR®, an iodine-131-labeled antibody targeting CD20 posi-
tive B-lymphoma cells. Using dosimetry, physicians can use a low
dose (5 mCi) and directly measure this TCA clearance rate. Patients
with high tumor burden, splenomegaly, or bone marrow involve-
ment tend to have faster clearance. Hence, the therapeutic dose
(up to 90 mCi) can be prospectively individualized by using an
equation (52).
By allowing patient selection and efficacy as well as toxicity
monitoring, the potential success of pivotal trials using these ther-
anostic strategies will allow the technological advancement and
clinical benefit improvement of personalized medicine. Table 6
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Table 6 | Clinical stage theranostics.
Organization Rx compound Dx compound Targeting moiety Target Configuration
type
Development
stage
Endocyte Vinca alkaloid Technetium-99m Folate Folate receptors Figure 2A Phase 3
Morphotek Iodine-131 Iodine-131 Chlorotoxin Annexin A2 Figure 2C Phase 2
GlaxoSmithKline Iodine-131 Iodine-131 Tositumomab (murine
IgG2a)
CD20 Figure 2C Approved
(Bexxar®)
Institut Jules Bordet Lutetium-177 Gallium-68 Octreotide
(somatostatin analog)
Somatostatin
receptor
Figure 2A Phase 2
Peregrine Neutralizing mAb F(ab′)2-indium-124 Bavituximab Phosphatidylserine Figure 2Aa Phase 1b/Phase 3c
Memorial Sloan-Kettering
Cancer Center
Iodine-131 indium-124 8H9 (murine IgG1) B7-H3 Figure 2A Phase 1
University Medical
Centre Groningen
Neutralizing mAb Zirconium-89 Trastuzumab HER2 Figure 2Aa Phase 1/2
Institut Jules
Bordet/Roche
Maytansine Zirconium-89 Trastuzumab HER2 Figure 2A Phase 2
Areva Med LLC Lead-212 Lead-212 Trastuzumab HER2 Figure 2C Phase 1
aRx compound is a naked chimera IgG with target-neutralizing activity;
bDx compound;
cRx compound.
contains a list of clinical stage theranostics being developed for
oncology.
CONCLUSION AND FUTURE DIRECTIONS
The use of personalized medicine has many attributes that make
the practice invaluable to patients, the pharmaceutical industry,
and the healthcare system. The ability to predefine patients with
a high likelihood to respond to a given therapy will provide ben-
efit to all parties. For patients, the ability to predict response will
improve therapeutic outcome while avoiding unnecessary treat-
ment with ineffective, potentially toxic drugs and thereby lead to
a better quality of life, if not a cure. For the pharmaceutical indus-
try, predictive biomarkers (i.e., informative CDx) may improve the
probability of success that a drug will provide meaningful clini-
cal results in trials leading to higher approval rates by regulatory
authorities and value-creation for the industry and patients alike.
For the healthcare system, the ability to avoid futile, potentially
toxic therapies will reduce not only drug costs but overall health-
care costs and potentially improve patient health by identifying
agents that have a higher probability of success in treating their
specific disease. While these attributes are compelling, the ability
to implement platforms to support personalized medicine remains
challenging. Attempts to identify disease-specific targets or mole-
cular signatures that can provide predictive response outcomes
are ongoing across the pharmaceutical industry and academia
alike for many indications. While a few successful examples have
been achieved, the majority of development programs are hand-
icapped by the paucity of targets associated with disease as well
as the time and effort required to validate molecular signatures
that can unequivocally and reproducibly predict patient response
to non-targeted SCEs.
As the industry refines its technologies and methods to improve
upon personalized medicine, a few platforms exist today that may
support this initiative in real-time clinical trials. Of particular note
is the use of NPs and NOPs that can be conjugated to a therapeu-
tic agent to improve disease-specific uptake of cytotoxic agents
and patient response. As discussed above, the use of theranostic
strategies employing, for example, a TCA and its co-developed
diagnostic vector for in vivo prescreening of patients for tumor-
specific uptake, offers the opportunity to identify patients with
the highest likelihood of benefiting from the TCA therapy. Real-
time theranostic imaging strategies may offer an alternative or
supplemental approach to the more time consuming pharmacoge-
nomics and/or molecular marker signature analyses for predicting
response, although these approaches may yet prove complemen-
tary rather than mutually exclusive. Moreover, the application of
NP or NOP containing vectors that enable their use for therapy
in a broader range and higher frequency of cancers may offer bet-
ter options than antibody-based therapies whose target is likely
restricted to a few indications or across several indications at a low
frequency. Other targeting agents in addition to NP and NOPs
have also been formatted to support theranostic therapies. Stud-
ies in several cancers have found that cell surface proteins such
as the folate receptor alpha (FOLR1), a highly expressed protein
on ovarian and other epithelial derived cancers can be exploited
in a theranostic context (53–55). Strategies to develop conjugates
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that can be selectively taken up via FOLR1 have been pursued in
clinical trials whereby results from these studies have shown that
patients whose tumors with uptake of an imaging-folate diagnostic
conjugate have enhanced clinical response to a folate–vinblastine
therapeutic conjugate compared to patients who do not have
folate diagnostic vector uptake (56). Similar approaches to develop
conjugate-imaging/conjugate-therapeutic vector pairs have sug-
gested improved patient selection and therapeutic responses.
Other examples of diagnostic and therapeutic targeting vector
pairs have employed NP technologies to co-develop complexes
containing diagnostic agents and an anti-cancer agent, including
siRNAs (57). In all cases, the use of TCA and a co-developed tar-
geting diagnostic vector offer alternative methods for delivering
personalized therapies to patients in need of new treatments. The
key, therefore, for the successful and continued evolution toward
personalized medicine is co-development of both the therapeutic
and the diagnostic agents as well as diagnostic modalities begin-
ning at the time of target discovery and preclinical studies and
continuing through clinical validation and regulatory approvals.
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